Scholarlink

Purpose <p>To explore the clinical significance of pyruvate dehydrogenase kinase 4 (PDK4) in pan-cancer and its potential as a tumor biomarker and immunotherapy target.</p> Methods <p>Public databases (HPA, TCGA, GTEx, etc.) were used to analyze PDK4 expression, diagnostic efficacy, prognostic value, immune characteristics, genetic alterations, and immunotherapy responsiveness in pan-cancer. Targeted drugs were predicted via molecular docking.</p> Results <p>PDK4 is predominantly expressed in skeletal muscle and specific cell types (basal prostatic cells, skeletal myocytes, etc.) in normal tissues. In most tumors, PDK4 expression is downregulated, with high diagnostic efficacy (AUC &gt; 0.7 for most cancers) and independent prognostic value for overall survival (OS) in multiple tumors. PDK4 is enriched in immune cells (monocytes, myeloid DC) and positively correlated with immune infiltration and checkpoint genes. High PDK4 expression improves progression-free survival (PFS) in anti-PD-L1-treated patients, and tretinoin binds stably to PDK4.</p> Conclusions <p>PDK4 is a promising pan-cancer diagnostic/prognostic biomarker and potential immunotherapy target, providing a basis for personalized cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-dimensional analysis reveals the potential of PDK4 as a tumor biomarker and target for immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月23日

查看全文
  • Yaxing Deng,
  • Xin Wang,
  • Mei Zeng,
  • Chenglin Wang

摘要

Purpose

To explore the clinical significance of pyruvate dehydrogenase kinase 4 (PDK4) in pan-cancer and its potential as a tumor biomarker and immunotherapy target.

Methods

Public databases (HPA, TCGA, GTEx, etc.) were used to analyze PDK4 expression, diagnostic efficacy, prognostic value, immune characteristics, genetic alterations, and immunotherapy responsiveness in pan-cancer. Targeted drugs were predicted via molecular docking.

Results

PDK4 is predominantly expressed in skeletal muscle and specific cell types (basal prostatic cells, skeletal myocytes, etc.) in normal tissues. In most tumors, PDK4 expression is downregulated, with high diagnostic efficacy (AUC > 0.7 for most cancers) and independent prognostic value for overall survival (OS) in multiple tumors. PDK4 is enriched in immune cells (monocytes, myeloid DC) and positively correlated with immune infiltration and checkpoint genes. High PDK4 expression improves progression-free survival (PFS) in anti-PD-L1-treated patients, and tretinoin binds stably to PDK4.

Conclusions

PDK4 is a promising pan-cancer diagnostic/prognostic biomarker and potential immunotherapy target, providing a basis for personalized cancer treatment.